Summary
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2020, to disclose preliminary financial information and corporate updates presented at the 38th Annual J.P. Morgan Healthcare Conference. The key takeaway for investors is the strong performance of EYLEA®, with preliminary full-year 2019 U.S. net product sales exceeding $4.64 billion, including approximately $1.22 billion in the fourth quarter of 2019. This update provides an early look at the company's revenue generation from its flagship product ahead of official fourth-quarter earnings.
Key Highlights
- 1Preliminary full-year 2019 U.S. net product sales for EYLEA® (aflibercept) Injection were approximately $4.64 billion.
- 2Preliminary fourth-quarter 2019 U.S. net product sales for EYLEA® were approximately $1.22 billion.
- 3The corporate update was delivered by key executives, including the CEO and Chief Scientific Officer, at the J.P. Morgan Healthcare Conference.
- 4This filing incorporates by reference the presentation made at the conference, which is filed as Exhibit 99.1.
- 5The information provided is preliminary and unaudited.
- 6The filing serves as a Regulation FD disclosure, disseminating material information to all investors simultaneously.